Somatostatin analogs are first line treatment for patients with metastatic neuroendocrine tumours (NET). There are currently two different types of somatostatin analogs available: octreotide LAR and lanreotide. Both are given to patients as injections every four weeks. Octreotide LAR is given as a deep injection into the muscle (intramuscular or IM injection) whereas lanreotide is given under the skin (subcutaneous or SC injection). While both medications have been shown to benefit patients with metastatic NET, we don't know if one works better than the other, as there has been no high quality research comparing them head to head. Some smaller studies have suggested that there might be an advantage of lanreotide over octreotide LAR since giving the octreotide injection is technically more difficult and can end up in the wrong spot, resulting in the patient not getting full benefit of the medication. Furthermore, lanreotide has improved convenience for patients. With its simpler SC administration protocol, lanreotide can be given at home by patients/caregivers, while octreotide must be given by a trained nurse. The goal of our study is to compare outcomes for patients taking lanreotide with patients taking octreotide LAR. We will look at outcomes related to their cancer ( i.e. how well their symptoms are controlled and how long it takes for their cancer to progress) as well as their quality of life and perspectives about the treatment. Our results are expected to reveal whether two different somatostatin analogues, which are used interchangeably in NET treatment, differentially impact clinical outcomes and/or patient experiences.

This study looks at whether wearing a custom mouthpiece during sleep can improve sleep quality and recovery in healthy adults. We are testing a device that gently moves the lower jaw forward to help keep the airway open while you sleep. This may help with breathing, sleep quality, and how well your body recovers overnight. Participants will wear a wristwatch device to track their sleep, heart rate, and oxygen levels. They will also use two different mouthpieces during the study—one active device and one comparison device—to see if there are any differences.

This study uses special sound waves, called low intensity frequency ultrasound to gently affect small areas of the brain for a short time. There is no surgery involved, and it is safe to use. By watching how a person moves during tasks before and after the sound waves are used, we can learn how the brain helps control movement. In the future, this research might help create better treatments for conditions like Parkinson’s disease.

This study is for children aged between 2 and 18 years who have Lennox-Gastaut Syndrome or Dravet Syndrome taking artisanal CBD to take part in a 20-week long clinical research study. The primary purpose is to investigate the best way to transition these children from artisanal CBD to a pharmaceutical-grade version of CBD called Epidiolex.

This study is evaluating an investigational treatment for Eosinophilic Esophagitis (EoE) called EP-104GI, which may help reduce inflammation and improve symptoms. EP-104GI is a long-acting injectable corticosteroids [fluticasone propionate] to be injected directly into the esophagus during an Endoscopy procedure.

This study is evaluating a new wearable heart monitor called HeartWatch. The goal is to see whether it records heart rhythm information as well as standard heart monitors that are currently used in clinics. People whose doctor has recommended, or may recommend, a heart monitor to check their heart rhythm may be able to take part. Participants in the study will wear the conventional heart monitor that is prescribed as part of their usual care. They will also wear the HeartWatch device so that researchers can compare the recordings from the two devices. The HeartWatch device is worn on the upper arm using a band. It continuously records heart rhythm data.

Many people with depression do not get better with the standard treatments. Ketamine treatment has become a strong and hopeful therapy for this kind of depression. Experts know that ketamine can help unipolar and bipolar treatment resistant depression. But, some questions remain. Ketamine treatment can make you feel disconnected from your body (dissociation effects). Some people may also abuse ketamine and develop an addiction. As such, more research is needed about dissociation effects and addiction potential. So, we are doing this study to learn more about the benefits and risks of ketamine treatment.

Many individuals with neurodevelopmental disorders have behaviours of concern, like aggression or self-injury. These behaviours can cause harm to the child themselves or others. These behaviours are hard to treat because we don't understand them very well. Researchers and doctors need a good way to measure behaviours of concern so they can figure out what helps. To help, we are developing a new scale, the Behaviours of Concern Assessment Instrument (BoCAI). We need caregivers to use the BoCAI and provide feedback to help us make the BoCAI better.

Post stroke fatigue afflicts as many as 70% of the 400,000 Canadians with stroke. There are no treatments for post stroke fatigue supported by research studies, however, exercise and the medication Modafinil have shown promise in alleviating symptoms in small studies. For this study we are looking at combining Modafinil with an instructor-led, home-based exercise program based on the “Fitness and Mobility Exercise (FAME)” program to help improve fatigue symptoms after stroke. A home-based exercise program delivered by videoconference allows participants to join exercise sessions over video from their homes, without having to travel to a different location. The purpose of this study is to: - Test whether Modafinil and exercise can improve the symptoms of post-stroke fatigue - Investigate the effects of Modafinil and exercise on other areas including but not limited to quality of life, fitness, mood, and health care utilization.

This study explores how your community placement during pre-clerkship has influenced your experience in clerkship. During your first two years of medical school, you completed a year-long placement with a community organization as part of the Community Engaged Learning program. Now that you are in clerkship and working in clinical settings like hospitals, we want to understand whether and how those community experiences have shaped the way you interact with patients, make clinical decisions, and think about your role as a future doctor. We are interested in hearing about what you remember most from your community placement, whether you've found yourself applying any lessons from that experience during your clinical rotations, and what aspects of the program were most meaningful or could be improved. Your insights will help us understand the lasting impact of community-based learning and will inform improvements to the program for future medical students. If you choose to participate, you will join a one-on-one interview with a member of our research team via Zoom. The interview will take about 45-60 minutes, and you'll receive the questions in advance so you can think about your experiences. We'll ask you to share examples of how your community placement has or hasn't influenced your work in clerkship, what elements of the program stood out to you, and what suggestions you have for making it better. Your participation is completely voluntary, and your honest feedback, whether it be positive or critical, is valuable and will not affect your standing in the medical program in any way. You will receive a $10 giftcard as compensation for your time.